The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study

about

Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis.Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.

P2860

Q47152972-9A233E45-B3BD-4F0E-BAEB-7D5C595234FD Q55247585-66BBA88A-5EF9-44B9-B4C1-631EC60EE101

P2860

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study

Item

http://www.wikidata.org/entity/Q41036693

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The Association between Phosph ...... Results from the REDUCE Study

@en

type

Item

label

The Association between Phosph ...... Results from the REDUCE Study

@en

prefLabel

The Association between Phosph ...... Results from the REDUCE Study

@en

P1476

The Association between Phosph ...... Results from the REDUCE Study

@en

P2093

Adriana C Vidal

http://www.w3.org/2001/XMLSchema#string

Gerald L Andriole

http://www.w3.org/2001/XMLSchema#string

Juzar Jamnagerwalla

http://www.w3.org/2001/XMLSchema#string

Lauren E Howard

http://www.w3.org/2001/XMLSchema#string

Ramiro Castro-Santamaria

http://www.w3.org/2001/XMLSchema#string

Stephen J Freedland

http://www.w3.org/2001/XMLSchema#string

P2860

Statin use and risk of prostate cancer: a meta-analysis of observational studies

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis.

Three-year update of sildenafil citrate (Viagra) efficacy and safety.

Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.

Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study

Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study

Definitions/epidemiology/risk factors for sexual dysfunction.

Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.

Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.

P304

715-720

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2016.03.172

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

196

http://www.w3.org/2001/XMLSchema#string

P50

Daniel M. Moreira

P577

2016-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27060053

http://www.w3.org/2001/XMLSchema#string

P932

5014695

http://www.w3.org/2001/XMLSchema#string

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study

about

P2860

P2860

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932